Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 13Thoracic 4Gastrointestinal 3Dermatologic 3Gynecologic 2Breast 2

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 4Skin Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vipoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Mycosis Fungoides 1

Interventions

pembrolizumab 58Nivolumab 37aldesleukin 16Cyclophosphamide 15atezolizumab 12Specimen Handling 11Radiosurgery 10Paclitaxel 10Magnetic Resonance Spectroscopy 10Ipilimumab 9Interleukin-2 9fludarabine 8fludarabine phosphate 7Docetaxel 7Carboplatin 7avelumab 6Radiotherapy 6durvalumab 5Peripheral Blood Stem Cell Transplantation 5Immune Checkpoint Inhibitors 5Cisplatin 5Bevacizumab 5tislelizumab 4temsirolimus 4spartalizumab 4Sirolimus 4Pemetrexed 4Oxaliplatin 4Leucovorin 4Cryosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Capecitabine × Dermatologic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Recruiting
214 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡